低剂量氯胺酮输注联合标准循证治疗多发肋骨骨折无获益
这项前瞻性随机安慰剂对照试验纳入50例成人(18岁及以上)且至少有3处肋骨骨折的患者,1:1随机接受持续低剂量氯胺酮输注(LDKI,0.1 mg/kg/h)或安慰剂(0.9% NaCl)输注不超过48小时,所有患者均接受标准循证多学科肋骨骨折管理方案。主要结局为吗啡毫克当量(MME)用量或肺部并发症。结果显示两组第1天(p=0.961)、第2天(p=0.373)及总MME(p=0.946)均无差异;在接受研究药物≥40小时的受试者中总MME用量同样相似(p=0.924)。LDKI未改变输注后阿片类药物需求、住院时间、肺部并发症或再入院需求。
要点
- 在标准多模式循证镇痛方案基础上加用LDKI(0.1 mg/kg/h,持续≤48小时)未减少第1天MME(p=0.961)、第2天MME(p=0.373)或总MME(p=0.946)。
- 接受研究药物≥40小时的受试者中,LDKI组与安慰剂组总MME用量同样相似(p=0.924)。
- LDKI未改变输注后阿片类药物需求、住院时间、肺部并发症或再入院需求。
- 研究纳入50例成人(18岁及以上)且至少有3处肋骨骨折的患者,安慰剂组25例、LDKI组25例,两组年龄、损伤严重度评分和肋骨骨折数匹配良好。
适用人群与场景
- 成人(18岁及以上)钝性胸部创伤导致至少3处肋骨骨折的患者。
处置流程与药物剂量
- 所有患者均接受标准循证多学科肋骨骨折管理方案(包括多模式镇痛、肺部卫生和早期活动)。
- LDKI组:持续低剂量氯胺酮输注0.1 mg/kg/h,持续≤48小时;安慰剂组:0.9% NaCl输注≤48小时。
研究设计与关键结果
- 前瞻性随机安慰剂对照试验,50例受试者(安慰剂组25例,LDKI组25例)均接受研究药物输注;两组年龄、损伤严重度评分和肋骨骨折数匹配良好。
- 第1天MME两组无差异(p=0.961),第2天MME两组无差异(p=0.373),总MME两组无差异(p=0.946)。
- 接受研究药物≥40小时的受试者中,总MME用量同样相似(p=0.924)。
- LDKI未改变输注后阿片类药物需求、住院时间、肺部并发症或再入院需求。
证据类型、等级与局限
- 证据类型:前瞻性随机安慰剂对照试验;证据等级:治疗/管理,Level I。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在已建立的多模式循证方案基础上加用LDKI(0.1 mg/kg/h,持续≤48小时)未减少阿片类药物用量或影响肺部并发症,不支持将其作为该方案的常规附加镇痛措施。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Multiple rib fractures from blunt thoracic trauma cause significant morbidity. Optimal current management includes multimodal analgesia, pulmonary hygiene, and early mobilization. Low-dose ketamine infusion (LDKI) has been proposed as an adjunctive analgesic in this setting. A prior study reported decreased pain scores with LDKI in patients with multiple rib fractures. We hypothesized that LDKI would decrease morphine milligram equivalents (MMEs) in patients with multiple rib fractures.
METHODS: A prospective randomized placebo-controlled trial was performed in adult (18 years or older) patients with three or more rib fractures. A prestudy power analysis calculated an 80% chance of identifying a 15% decrease in MMEs with 50 subjects. The study was approved by the institutional review board and informed consent obtained in all subjects. Demographic (age, sex) and injury specific information (Injury Severity Score, number of rib fractures) were obtained. Subjects were randomized 1:1 to receive continuous LDKI (0.1 mg/kg/h) or placebo infusion (0.9% NaCl) for ≤48 hours. All patients received a standard evidence-based multidisciplinary protocol for rib fractures management. Primary outcome measure was MME use or pulmonary complications. Statistical comparison of LDKI versus placebo was performed using the Mann-Whitney U test.
RESULTS: All 50 enrolled subjects (placebo, 25; LDKI, 25) received study drug infusion. The two groups were well matched for age, Injury Severity Score, and number of rib fractures. We observed no differences in the Day 1 (p = 0.961), Day 2 (p = 0.373), or total MMEs (p = 0.946) between groups. Similar total MME use was observed when subjects who received ≥40 hours of study drug and were compared (p = 0.924). Use of LDKI did not alter subsequent need for opiate analgesics postinfusion, hospital length of stay, pulmonary complications, or need for readmission.
CONCLUSION: The addition of LDKI to an established multimodal, evidence-based protocol for management of multiple rib fractures did not decrease opiate usage or impact pulmonary complications.
LEVEL OF EVIDENCE: Therapeutic/Care Managaement; Level I.
参考来源
- Macheel C, Farhat J, Gipson J, et al. No benefit from the addition of low-dose ketamine infusion to standard evidence-based care of patients with multiple rib fractures. J Trauma Acute Care Surg. 2024. PMID: 39443839. doi:10.1097/TA.0000000000004398
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。